
Sign up to save your podcasts
Or


In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease
By JAMA Network4.6
162162 ratings
In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease

6,784 Listeners

43,730 Listeners

38,708 Listeners

21,628 Listeners

139 Listeners

318 Listeners

699 Listeners

499 Listeners

761 Listeners

884 Listeners

3,348 Listeners

21 Listeners

12 Listeners

16 Listeners

7 Listeners

19 Listeners

29 Listeners

196 Listeners

90 Listeners

363 Listeners

6,421 Listeners

19 Listeners